ElevateBio has $1.3B on record. The latest round is a $401M Series D (May 2023). Size your own round against the evidence it must buy, not against the stage letter.
Key takeaways
- Round size should be derived from the evidence the next investor needs, not from the stage label.
- Named participants on a record tell you which funds write at this size and stage.
- Plan the raise timeline backwards from your cash-out date, with a third added for slippage.
A company's funding history is a sequence of promises kept or renegotiated. When the latest round is a small share of lifetime capital, the earlier rounds are still doing most of the work on the cap table.
The record here belongs to David Hallal, founder of ElevateBio (Cambridge, United States).
| | | |---|---| | Founder | David Hallal | | Company | ElevateBio (Cambridge, United States) | | Total raised | $1.3B | | Latest round | Series D — $401M | | Round date | May 2023 | | Named participants on record | AyurMaya Capital Management, Matrix Capital Management, Woodline, Lee Family Office, Novo Nordisk, The Invus Group |
This round is 32% of everything raised to date, so earlier rounds still shape the cap table.
The round size sets the next evidence bar. Investors size the following round against what this one was expected to buy. Write that expectation down before you sign.
Named participants signal the buyer pool. AyurMaya Capital Management, Matrix Capital Management, Woodline, Lee Family Office, Novo Nordisk, The Invus Group are on record here. Funds with that profile are the realistic audience for a comparable raise.
Timing is data. The round closed in May 2023. Fundraises take longer than founders plan; count backwards from the date you need cash, not from the date you want a term sheet.
1. Write the two or three pieces of evidence your next round must show. 2. Cost out the months and headcount required to produce that evidence, then add a third for slippage. 3. Build the investor list from funds that have written cheques of this size at this stage, not from brand preference. 4. Ask each lead what they expect to see at the next round, and hold them to it in writing.
The letter on the round matters far less than whether the money buys the evidence the next buyer needs.
Frequently asked questions
- How much has David Hallal raised for ElevateBio?
- ElevateBio has $1.3B in disclosed funding on record, most recently a $401M Series D in May 2023.
- Who invested in ElevateBio?
- Named participants on record include AyurMaya Capital Management, Matrix Capital Management, Woodline, Lee Family Office, Novo Nordisk, The Invus Group. Records list participants, not allocations or terms.
- Where do these figures come from?
- Structured founder funding records: total raised, round stage, round amount, round date and named participants. They exclude valuation, terms and board composition.
